A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) (NCT07202546)
A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of Oral VH4524184 Coadministered With Emtricitabine and Tenofovir Alafenamide in Treatment Naive Viremic Persons With HIV-1 (INNOVATE Study)
🩺 Plain-English Summary (8th-Grade Level)
This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Bakersfield, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (123 Sites)
Showing the first 25 of 123 sites.
- GSK Investigational Site — Bakersfield, California
- GSK Investigational Site — Palm Springs, California
- GSK Investigational Site — West Hollywood, California
- GSK Investigational Site — Aurora, Colorado
- GSK Investigational Site — New Haven, Connecticut
- GSK Investigational Site — Ft. Pierce, Florida
- GSK Investigational Site — Hollywood, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami Gardens, Florida
- GSK Investigational Site — Oakland Park, Florida
- GSK Investigational Site — Orlando, Florida
- GSK Investigational Site — Orlando, Florida
- GSK Investigational Site — West Palm Beach, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Macon, Georgia
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Louisville, Kentucky
- GSK Investigational Site — Columbia, Missouri
- GSK Investigational Site — Kansas City, Missouri
- GSK Investigational Site — Omaha, Nebraska
- GSK Investigational Site — Hackensack, New Jersey
- GSK Investigational Site — Newark, New Jersey
- GSK Investigational Site — Albany, New York
- GSK Investigational Site — Manhasset, New York
- GSK Investigational Site — Charlotte, North Carolina
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV Infections
- Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention — Chicago, Illinois
- The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City — New York, New York
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults — Birmingham, Alabama
- Clinical Decision Support for PrEP — Los Angeles, California
- Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care — Baltimore, Maryland
- A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV — Las Vegas, Nevada
Explore by condition: All HIV Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.